Key Stats for Stryker Stock
- Price change for Stryker stock in last 1 month: -20%
- $SYK Stock Price as of Sep. 8: $276
- 52-Week High: $393
- $SYK Stock Price Target: $383
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Stryker (SYK) stock has been under pressure, falling 30% over the past year and now trading almost at its 52-week low.
The medical device maker gave an update at the Wells Fargo Healthcare Conference on September 8, and while management tried to reassure investors, the message was mixed.
The company kept its full-year 2026 organic growth guidance unchanged at 8.3% to 9.3%, with a midpoint of 8.8%.
But CFO Preston Wells admitted the path to get there has gotten bumpier. Two parts of the business are causing the most trouble.
First is peripheral vascular. Stryker is still dealing with fallout from an earlier cyber incident that disrupted manufacturing.
Supply problems there dragged growth down by 70 to 80 basis points in both Q2 and Q3, and management now expects the same drag to continue into Q4.
The issue isn’t demand. It’s supply. Stryker simply can’t make enough product yet to fully stock its top customers, let alone go after new ones.
That means the company is losing some share in this space, since these are often emergency procedures where doctors need product on hand right away.
Second, joint replacement has been softer than expected, especially hip procedures in Europe.
Wells pointed to funding pressures, strikes, and broader economic strain overseas.
In the U.S., the slowdown looked more like normal summer seasonality, with patients and surgeons taking vacation time in July and August.
On the positive side, Stryker’s capital equipment business and its trauma and extremities unit are both performing well.
Capital equipment orders remain strong, and trauma products, including the company’s Pangea platform, continue to grow faster than the overall market.
These stronger areas are helping offset the weaker ones.
See analysts’ growth forecasts and price targets for Stryker stock (It’s free) >>>
What the Market Is Telling Us About Stryker Stock
Despite the stock’s decline, InvestingPro’s analysis suggests Stryker stock is undervalued at current prices, placing it among the platform’s most undervalued companies.
That’s a notable disconnect. The market is pricing in real near-term uncertainty around supply chains and softer ortho demand, but some analysts see the selloff as overdone given the company’s longer-term product pipeline.
Management is leaning on that pipeline for confidence. Mako robotic surgery, the newer Mako RPS system, and the AVS acquisition’s entry into interventional vascular lithotripsy are all cited as reasons to expect a stronger 2027, assuming supply issues get resolved.
A major clinical study called PEERLESS II, expected to read out next year, could also help grow the overall peripheral vascular market.
For now, though, Stryker stock reflects a company caught between real short-term execution problems and a leadership team that insists the underlying business is healthy.
Investors will get a clearer picture when Stryker reports its Q3 results and updates guidance with more complete data.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Stryker Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
